Clinical director of the Irish health technology assessment (HTA) body National Centre for Pharmacoeconomics (NCP), Michael Barry, MB, FRCPI, PhD, recently said in an interview with Irish media that the lack of uptake of biosimilars in Ireland is “an issue that should be tackled,” and he proposed approaches to do just that.
Clinical director of the Irish health technology assessment (HTA) body National Centre for Pharmacoeconomics (NCP), Michael Barry, MB, FRCPI, PhD, recently said in an interview with Irish media that the lack of uptake of biosimilars in Ireland is “an issue that should be tackled.”
He went on to explain that “The [Health Service Executive, HSE] needs to take this one seriously and to have a good quality team producing a policy and also implementing it and, in addition, empowering excellent pharmacy units in our hospitals.”
Click here to read more about biosimilars in Ireland.
Barry explained that, among his colleagues, there is an appreciation that safety and efficacy of drug products is important, but prescribers should not overlook the cost issue of medicines. He also had recommendations for how to approach the issue, beginning with the creation of a policy that states that, unless there are extenuating circumstances, a patient starting treatment on a biologic should begin with a biosimilar.
“Then you’ve got to put in the structures to enable this to happen at a hospital level. We have spent the last 5 years concentrating on community expenditure because that is where most of it takes place, but we need to get to grips with hospital prescribing,” he said.
Though the United States has also seen a similar lack of biosimilar uptake, the nations differ in terms of their challenges and approaches to addressing them. While CMS recently announced that it would allow Medicare Advantage plans to use step therapy that could involve starting patients on biosimilars, that policy initiative does not extend to commercial plans (and experience with step therapy used in commercial plans to date has shown that biosimilars are not typically used first). Neither has the United States made special initiatives to address hospital- versus community-based biosimilar prescribing.
Furthermore, in the United States, there are just 4 biosimilars on the market, compared with Ireland’s 11 reimbursable biosimilars (as of the date of Ireland’s Minister for Health publication of a consultation paper on developing a national policy on biosimilars).
The slow biosimilar uptake in both the United States and Ireland has cost each country’s respective health system greatly, however. Last month, Medicines for Ireland released a report stating that Ireland’s policies are keeping the nation from benefitting from €25m (approximately $29 million) in annual savings to its national health system. Similarly, in the United States, biosimilars had been projected to save nearly $54 billion from 2017 to 2026, but the actual realized savings thus far are only “a fraction of even the most conservative initial estimates,” said FDA Commissioner Scott Gottlieb, MD, in a recent statement.
What remains the same throughout any market looking to increase the use of biosimilars is that it is not a feat that can be accomplished by a single organization or government entity. During the announcement of the FDA’s Biosimilar Action Plan, Gottlieb stated that achieving the cost savings projected for biosimilars will require actions from both the public and private sector. Barry is of a similar mindset, explaining that the benefits of biosimilars are obvious, but “resources are needed to put the strategy in place.”
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.